These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8840318)

  • 1. Influence of aluminium overload on the course of post-transplant parathyroid function.
    Garay G; Grosso S; Douthat W; Fernández Martín JL; Cannata J; Massari PU
    Nephrol Dial Transplant; 1996; 11 Suppl 3():65-8. PubMed ID: 8840318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time course and functional correlates of post-transplant aluminium elimination.
    Grosso S; Douthat W; Garay G; de Arteaga J; Boccardo G; Fernández Martín JL; Canteros A; Cannata Andía J; Massari P
    Nephrol Dial Transplant; 1998; 13 Suppl 3():98-102. PubMed ID: 9568831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations.
    Torres A; Rodríguez AP; Concepción MT; García S; Rufino M; Martín B; Pérez L; Machado M; de Bonis E; Losada M; Hernández D; Lorenzo V
    Nephrol Dial Transplant; 1998; 13 Suppl 3():94-7. PubMed ID: 9568830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study.
    Evenepoel P; Claes K; Kuypers D; Maes B; Bammens B; Vanrenterghem Y
    Nephrol Dial Transplant; 2004 May; 19(5):1281-7. PubMed ID: 14993493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
    Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules.
    Barata JD; D'Haese PC; Pires C; Lamberts LV; Simões J; De Broe ME
    Nephrol Dial Transplant; 1996 Jan; 11(1):125-32. PubMed ID: 8649620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
    McCarthy JT; Milliner DS; Johnson WJ
    Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Level-dependent inhibitory effect of hyperaluminaemia on parathyroid hormone secretion in patients with end-stage renal failure.
    Fernández E; Amoedo ML; Montoliu J
    Eur J Med; 1992 Dec; 1(8):482-4. PubMed ID: 1341207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload.
    D'Haese PC; Couttenye MM; Goodman WG; Lemoniatou E; Digenis P; Sotornik I; Fagalde A; Barsoum RS; Lamberts LV; De Broe ME
    Nephrol Dial Transplant; 1995 Oct; 10(10):1874-84. PubMed ID: 8592597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral phosphorus supplementation on mineral metabolism of renal transplant recipients.
    Caravaca F; Fernández MA; Ruiz-Calero R; Cubero J; Aparicio A; Jimenez F; García MC
    Nephrol Dial Transplant; 1998 Oct; 13(10):2605-11. PubMed ID: 9794568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid function after successful renal transplantation.
    Botha JF; Botha JR
    S Afr J Surg; 1997 Aug; 35(3):113-6. PubMed ID: 9429326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of aluminium on parathyroid hormone levels in haemodialysis patients.
    Cannata JB; Briggs JD; Junor BJ; Beastall G; Fell GS
    Proc Eur Dial Transplant Assoc; 1983; 19():244-7. PubMed ID: 6878239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypercalcaemia, hypermagnesaemia, hyperphosphataemia and hyperaluminaemia in CAPD: improvement in serum biochemistry by reduction in dialysate calcium and magnesium concentrations.
    Hutchison AJ; Were AJ; Boulton HF; Mawer EB; Laing I; Gokal R
    Nephron; 1996; 72(1):52-8. PubMed ID: 8903861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parathyroid subcutaneous pre-sternal transplantation after parathyroidectomy for renal hyperparathyroidism. Long-term graft function.
    Echenique-Elizondo M; Amondarain JA; Vidaur F; Olalla C; Aribe F; Garrido A; Molina J; Rodrigo MT
    World J Surg; 2007 Jul; 31(7):1403-9. PubMed ID: 17516108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of aluminium hydroxide on serum ionised calcium, immunoreactive parathyroid hormone, and aluminium in chronic renal failure.
    Biswas CK; Arze RS; Ramos JM; Ward MK; Dewar JH; Kerr DN; Kenward DH
    Br Med J (Clin Res Ed); 1982 Mar; 284(6318):776-8. PubMed ID: 6802224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients.
    Kan WC; Chien CC; Wu CC; Su SB; Hwang JC; Wang HY
    Nephrol Dial Transplant; 2010 May; 25(5):1604-8. PubMed ID: 19948879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients.
    Goldberg DI; Dillon MA; Slatopolsky EA; Garrett B; Gray JR; Marbury T; Weinberg M; Wombolt D; Burke SK
    Nephrol Dial Transplant; 1998 Sep; 13(9):2303-10. PubMed ID: 9761513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aluminium overload of parathyroid glands in haemodialysed patients with hyperparathyroidism: effect on bone remodelling.
    Berland Y; Charbit M; Henry JF; Toga M; Cano JP; Olmer M
    Nephrol Dial Transplant; 1988; 3(4):417-22. PubMed ID: 3140127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.